Close menu




July 10th, 2025 | 07:25 CEST

Small-cap disrupts billion-dollar market: Johnson & Johnson, Merck KGaA, and NetraMark

  • Biotechnology
  • Biotech
  • AI
  • healthtech
Photo credits: pexels.com

When it comes to making people healthy, progress is what matters most. New drugs must be better and safer than old ones. To ensure that these requirements are met, comprehensive testing procedures are carried out by drug regulatory authorities. However, despite ever-expanding knowledge and modern methods, almost 90% of clinical trials still fail. When considering that the development of a drug costs an average of USD 2.6 billion and usually takes more than ten years, it becomes clear what a risk biotech companies and pharmaceutical multinationals are taking. This is precisely where NetraMark's business model comes in, offering the entire industry unparalleled leverage.

time to read: 3 minutes | Author: Nico Popp
ISIN: JOHNSON + JOHNSON DL 1 | US4781601046 , MERCK KGAA O.N. | DE0006599905 , NETRAMARK HOLDINGS INC | CA64119M1059

Table of contents:


    Every year, around USD 250 billion is invested in research and development

    Almost all major industry players recognize that research is essential: Johnson & Johnson invests around USD 14 billion in research and development every year, and the Darmstadt-based Merck Group spent around EUR 2.3 billion in 2024. If all research expenditure is added together, the figure is even higher – around USD 247 billion in 2022. The trend is likely to persist after the COVID-19 pandemic ends, with spending expected to increase. What if there were ways to channel these billions more effectively and use them in a more targeted way?**

    NetraMark makes clinical trials cheaper and faster

    Canadian biotech service provider NetraMark is addressing precisely this issue and offers the industry NetraAI, an analytics platform for optimizing clinical trials. NetraMark's solution identifies patient subgroups that are unlikely to benefit from the investigational drug or are highly prone to placebo effects so that such subjects can be excluded from the trial. In this way, NetraMark aims to reduce the risk of clinical trials and make them more efficient. Imagine if a project could be scrapped in the first few months, rather than progressing to further, cost-intensive phases. What sounds like magic and a bit like trickery is desired by the US Food and Drug Administration and is addressed in guidelines – NetraMark is therefore acting in accordance with current practice.

    In May, NetraMark entered into a partnership with the globally recognized contract research organization Worldwide Clinical Trials, which will make NetraAI available to its clients. The associated multiplier effect is expected to lead to further partnerships with biotech companies or research institutions. The chances of this happening are good: according to industry analyses, AI systems could make clinical trials up to 70% cheaper and 80% faster by identifying suitable patients across locations and assisting in the selection of subgroups.

    Interest is growing accordingly: Large pharmaceutical companies are investing heavily in AI. One example is the German company Merck. The Darmstadt-based company announced a collaboration with AI start-up Quris in early 2025 to enable toxicity predictions early in the research process. Phase 1 studies determine whether active ingredients are toxic. NetraAI from NetraMark also aims to reduce risks in later phases, precisely where the greatest potential for costly setbacks lies.

    Rare diseases as a particular lever for NetraMark

    Research into active ingredients for rare diseases is also particularly costly. Among other things, the challenging recruitment of patients drives up costs. These include diseases of the central nervous system, for example. Johnson & Johnson is involved in this area with a nasal spray for depression, and Merck with two active ingredients for multiple sclerosis. NetraMark sees particularly strong growth potential in this area and believes that innovative approaches are in high demand here.

    Quick wins instead of lengthy development cycles – HealthTech in demand on the stock market

    While the business of large healthcare companies operates in long cycles and depends crucially on the success of research and development, NetraMark benefits from the enormous cost-cutting potential in this area. The fact that AI can make clinical trials 70% cheaper and 80% faster, as estimated by industry experts, is a huge lever. NetraMark is likely to have been on the radar of potential customers or cooperation partners for some time now.

    While shares in Johnson & Johnson and Merck KGaA have suffered losses over the past six months, NetraMark's business model is proving popular, with a whopping 30% increase in the past six months. With a valuation of just over EUR 60 million, a significant partnership with a pharmaceutical giant would be enough to fuel speculation about the share price. A takeover of NetraMark is also conceivable. The stock is an exciting bet on innovation in the healthcare sector. Since NetraMark helps companies become more cost-effective and faster, the risk-reward ratio appears promising.

    Watch YouTube video


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Carsten Mainitz on November 19th, 2026 | 05:20 CET

    Uranium and Reactor Technology: Standard Uranium, Cameco and SGL Carbon – Who Benefits Most from the Nuclear Comeback?

    • Uranium
    • Nuclear power
    • Nuclear energy
    • Reactors
    • Reactor technology
    • AI
    • Supply chains

    Nuclear power needs fresh supplies! Longer operating lifetimes, new reactors and power-hungry data centres are strengthening demand and fuelling optimism for the industry. Geopolitical tensions are pushing operators to secure supplies, while additional supply requires substantial capital and time. For investors, this opens up opportunities along the entire nuclear value chain. Standard Uranium starts at the very beginning, exploring for new deposits in Canada's Athabasca region. Cameco already generates revenue from uranium and fuel services and is also involved in reactor technology through Westinghouse. SGL Carbon, in turn, supplies speciality graphite for X-energy's reactors and recently secured another order worth around USD 90 million. Which company will take off now?

    Read

    Commented by Jens Castner on November 18th, 2026 | 05:40 CET

    Treasures from the depths, a slump in the stock market: Lynas, Almonty and Cameco tempt with low share prices

    • Critical raw materials
    • Rare earths
    • Tungsten
    • Uranium
    • Almonty Industries
    • Cameco
    • AI
    • Lynas Rare Earths

    Without rare earths, no electric motors; without tungsten, no defence industry; without uranium, no nuclear power. The West needs these raw materials more urgently than ever and depends on a handful of suppliers that mine in politically stable countries. Yet shares in Lynas Rare Earths, Almonty Industries and Cameco are falling as if there were no shortage – down by one-third to two-thirds from their highs for the year. We have taken a close look at the three producers following their latest quarterly results. One of the shares has reached bargain levels.

    Read